Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Impact of Minimal Residual Disease after Allografting Detected By JAK2V617F, MPL or Calreticulin in Myelofibrosis Patients

Nicolaus Kroeger, Anita Badbaran, Tatjana Zabelina, MD, Maximilian Christopeit, MD, Christine Wolschke, MD, Francis Ayuk, MD, Axel R. Zander, Professor, Haefaa Alchalby, MD, Ulrike Bacher, Ioanna N Triviai, PhD, Boris Fehse, PhD

Blood (2015) 126 (23): 4343.

https://doi.org/10.1182/blood.V126.23.4343.4343

Published: 2015

Journal Articles

Impact of Molecular Genetics on Disease-Free Survival in Myelofibrosis Patients Following Allogeneic Stem Cell Transplantation

Blood (2015) 126 (23): 352.

https://doi.org/10.1182/blood.V126.23.352.352

Published: 2015

Journal Articles

Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis

Nicolaus Kröger, Toni Giorgino, Bart L. Scott, Markus Ditschkowski, Haefaa Alchalby, Francisco Cervantes, Alessandro Vannucchi, Mario Cazzola, Enrica Morra, Tatjana Zabelina, Margherita Maffioli, Arturo Pereira, Dietrich Beelen, H. Joachim Deeg, Francesco Passamonti

Blood (2015) 125 (21): 3347–3350.

https://doi.org/10.1182/blood-2014-10-608315

Published: 2015

Journal Articles

Survival of Allogeneic Stem Cell Transplantation Vs Conventional Therapies per DIPSS Stratification in Patients with Primary Myelofibrosis Younger Than 65 Years: A Retrospective Analysis on 673 Patients

Nicolaus Kröger, MD, Toni Giorgino, PhD, Bart L Scott, MD, Marcus Ditschkowski, MD, Haefaa Alchalby, MD, Francisco Cervantes, MD PhD, Alessandro M. Vannucchi, MD, Mario Cazzola, MD, Enrica Morra, Tatjana Zabelina, MD, Margherita Maffioli, MD, Arturo Pereira, MD PhD, Dietrich Beelen, MD, H. Joachim Deeg, MD, Francesco Passamonti, MD

Blood (2014) 124 (21): 633.

https://doi.org/10.1182/blood.V124.21.633.633

Published: 2014

Journal Articles

Prognostic Impact of Splicing Factor Mutations in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Blood (2014) 124 (21): 3171.

https://doi.org/10.1182/blood.V124.21.3171.3171

Published: 2014

Journal Articles

18 f-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (PET/CT) for Assessment of Bone Marrow Metabolism in Patients with Myelofibrosis

Thorsten Derlin, MD, Haefaa Alchalby, MD, Peter Bannas, MD, Simon Veldhoen, MD, Guntram Büsche, MD, Ioanna N Triviai, PhD, Frank Bengel, Nicolaus Kröger, MD

Blood (2014) 124 (21): 1866.

https://doi.org/10.1182/blood.V124.21.1866.1866

Published: 2014

Journal Articles

Impact Of Conditioning Regimen, Donor Source, and DIPSS Score On Outcome Of Allogeneic Hematopoietic Stem Cell Transplantation For Myelofibrosis

Nicolaus Kröger, MD, Markus Ditschkowski, MD, Bart L Scott, MD, Tatjana Zabelina, MD, Haefaa Alchalby, MD, Dietrich Beelen, MD, H. Joachim Deeg, MD

Blood (2013) 122 (21): 712.

https://doi.org/10.1182/blood.V122.21.712.712

Published: 2013

Journal Articles

The Pan- JAK Inhibitor Ruxolitinib Impairs T-Cell Activation, Cytokine Production and Proliferation In Vivo and In Vitro

Thomas Stuebig, MD, Christine Wolschke, MD, Haefaa Alchalby, MD, Francis Ayuk, MD, Marion Heinzelmann, Ioanna Triviai, PhD, Anita Badbaran, York Hildebrandt, Nicolaus Kroeger, MD

Blood (2013) 122 (21): 2001.

https://doi.org/10.1182/blood.V122.21.2001.2001

Published: 2013

Journal Articles

Quality Of Life After Allogeneic Stem Cell Transplantation In Patients With Myelofibrosis (CMWP of EBMT)

Nora Machate, Haefaa Alchalby, MD, Susanne Sehner, Tatjana Zabelina, MD, Daniel Wolff, MD, Guido Kobbe, MD, Martin Bornhäuser, MD, Herrad Baurmann, MD, Wolfgang A Bethge, MD, Gerald Wulf, MD, Axel R. Zander, MD, Nicolaus Kröger, MD

Blood (2013) 122 (21): 2974.

https://doi.org/10.1182/blood.V122.21.2974.2974

Published: 2013

Journal Articles

The Kinetic Of Bone Marrow Fibrosis Regression Predicts Outcome In Myelofibrosis Patients After Allogeneic SCT

Nicolaus Kröger, MD, Haefaa Alchalby, MD, Tatjana Zabelina, MD, Hans-Michael Kvasnicka, MD, Juergen Thiele, MD, PhD, Guntram Büsche, MD, Hans Kreipe, MD

Blood (2013) 122 (21): 2078.

https://doi.org/10.1182/blood.V122.21.2078.2078

Published: 2013

Journal Articles

Ruxolitinib As Pretreatment Before Allogeneic Stem Cell Transplantation For Myelofibrosis

Nicolaus Kröger, MD, Haefaa Alchalby, MD, Markus Ditschkowski, MD, Dominik Wolf, MD, Gerald Wulf, MD, Tatjana Zabelina, MD, Christine Wolschke, MD, Thomas Stübig, MD, Francis Ayuk, MD

Blood (2013) 122 (21): 392.

https://doi.org/10.1182/blood.V122.21.392.392

Published: 2013

Journal Articles

Effective Prevention of Acute and Chronic Graft-Versus-Host Disease with Anti-Lymphocyte Globulin (ATG) without Increase of Relapse in HLA-Identical Sibling Peripheral Blood Stem Cell Transplantation.

Nicolaus Kröger, Tatjana Zabelina, Francis Ayuk, Haefaa Alchalby, MD, Christine Wolschke, Thomas Stübig, Evgeny Klyuchnikov, Jürgen Berger, Axel R. Zander, MD

Blood (2012) 120 (21): 3055.

https://doi.org/10.1182/blood.V120.21.3055.3055

Published: 2012

Journal Articles

Impact of ASXL1 Mutations On Outcome After Reduced Intensity Allograft in Patients with Myelofibrosis

Nicolaus Kröger, Christian Koenecke, Haefaa Alchalby, MD, Tatjana Zabelina, MD, Robin Bollin, Marten Gehlhaar, Vera Dobbernack, Sofia Kade, Liu Huang, Arnold Ganser, Francis Ayuk, MD, Christine Wolschke, MD, Felicitas Thol, MD, Michael Heuser, MD

Blood (2012) 120 (21): 1740.

https://doi.org/10.1182/blood.V120.21.1740.1740

Published: 2012

Journal Articles

Achievement of Sustained Molecular Remission Induces Long-Term Freedom From Disease After Autologous-Allogeneic Tandem Transplantation in Patients with Multiple Myeloma

Nicolaus Kröger, Tatjana Zabelina, MD, Francis Ayuk, MD, Christine Wolschke, MD, Haefaa Alchalby, Anita Badbaran, Djordje Atanackovic, M.D., Georgia Schilling, MD, Orhan Sezer, MD, PhD, Ulrike Bacher, MD, Thomas Stübig, MD, Boris Fehse, Ph.D., Axel R. Zander, MD

Blood (2011) 118 (21): 148.

https://doi.org/10.1182/blood.V118.21.148.148

Published: 2011

Journal Articles

Recovery of KIR Expression After Allogeneic Stem Cell Transplantation in Multiple Myeloma Patients

Thomas Stuebig, Michael Lioznov, Ulrike Fritsche-Friedland, Haefaa Alchalby, MD, Christine Wolschke, Francis Ayuk, Ulrike Bacher, MD, Axel R. Zander, Nikolaus Kroeger, MD

Blood (2011) 118 (21): 4555.

https://doi.org/10.1182/blood.V118.21.4555.4555

Published: 2011

Journal Articles

Donor Choice for Allogeneic Stem Cell Transplantation for AML – A Retrospective Single Centre Long-Term Analysis,

Francis Ayuk, MD, Friedericke Bernhardt, MD, Tatjana Zabelina, MD, Thomas Stübig, MD, Haefaa Alchalby, MD, Christine Wolschke, MD, Heinrich Lellek, MD, Ulrike Bacher, MD, Axel R. Zander, MD, Nicolaus Kröger

Blood (2011) 118 (21): 4147.

https://doi.org/10.1182/blood.V118.21.4147.4147

Published: 2011

Journal Articles

Long Term Follow-up of the Prospective Multicenter Study of reduced-Intensity Allogeneic Stem Cell Transplantation for Primary or Post ET/PV Myelofibrosis

Blood (2011) 118 (21): 1019.

https://doi.org/10.1182/blood.V118.21.1019.1019

Published: 2011

Journal Articles

Disease-Specific Recovery of Regulatory T Cell After Allogenic Stem Cell Transplantation

Thomas St\)big, Michael Lioznov, Ulrike Fritsche-Friedland, Haefaa Alchalby, Christine Wolschke, MD, Francis Ayuketang Ayuk, Ulrike Bacher, Axel R. Zander, MD, Nicolaus Kröger, MD

Blood (2010) 116 (21): 4689.

https://doi.org/10.1182/blood.V116.21.4689.4689

Published: 2010

Journal Articles

Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis

Haefaa Alchalby, Anita Badbaran, Tatjana Zabelina, Guido Kobbe, Joachim Hahn, Daniel Wolff, Martin Bornhäuser, Christian Thiede, Herrad Baurmann, Wolfgang Bethge, York Hildebrandt, Ulrike Bacher, Boris Fehse, Axel R. Zander, Nicolaus Kröger

Blood (2010) 116 (18): 3572–3581.

https://doi.org/10.1182/blood-2009-12-260588

Published: 2010

Journal Articles

Related Vs Unrelated Donors After Auto-Allo Tandem Stem Cell Transplantation for Newly Diagnosed Patients with Multiple Myeloma.

Nicolaus Kröger, MD, Tatjana Zabelina, Marion Heinzelmann, Georgia Schilling, Christine Wolschke, Heinrich Lellek, Thomas Stübig, Maite Lestin, Haefaa Alchalby, Francis Ayuk, Djordje Atanackovic, M.D., Ulrike Bacher, Boris Fehse, Axel R. Zander

Blood (2009) 114 (22): 1201.

https://doi.org/10.1182/blood.V114.22.1201.1201

Published: 2009

NARROW

Impact of Minimal Residual Disease after Allografting Detected By JAK2V617F, MPL or Calreticulin in Myelofibrosis Patients

Impact of Molecular Genetics on Disease-Free Survival in Myelofibrosis Patients Following Allogeneic Stem Cell Transplantation

Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis

Survival of Allogeneic Stem Cell Transplantation Vs Conventional Therapies per DIPSS Stratification in Patients with Primary Myelofibrosis Younger Than 65 Years: A Retrospective Analysis on 673 Patients

Prognostic Impact of Splicing Factor Mutations in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

18 f-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (PET/CT) for Assessment of Bone Marrow Metabolism in Patients with Myelofibrosis

Impact Of Conditioning Regimen, Donor Source, and DIPSS Score On Outcome Of Allogeneic Hematopoietic Stem Cell Transplantation For Myelofibrosis

The Pan- JAK Inhibitor Ruxolitinib Impairs T-Cell Activation, Cytokine Production and Proliferation In Vivo and In Vitro

Quality Of Life After Allogeneic Stem Cell Transplantation In Patients With Myelofibrosis (CMWP of EBMT)

The Kinetic Of Bone Marrow Fibrosis Regression Predicts Outcome In Myelofibrosis Patients After Allogeneic SCT

Ruxolitinib As Pretreatment Before Allogeneic Stem Cell Transplantation For Myelofibrosis

Effective Prevention of Acute and Chronic Graft-Versus-Host Disease with Anti-Lymphocyte Globulin (ATG) without Increase of Relapse in HLA-Identical Sibling Peripheral Blood Stem Cell Transplantation.

Impact of ASXL1 Mutations On Outcome After Reduced Intensity Allograft in Patients with Myelofibrosis

Achievement of Sustained Molecular Remission Induces Long-Term Freedom From Disease After Autologous-Allogeneic Tandem Transplantation in Patients with Multiple Myeloma

Recovery of KIR Expression After Allogeneic Stem Cell Transplantation in Multiple Myeloma Patients

Donor Choice for Allogeneic Stem Cell Transplantation for AML – A Retrospective Single Centre Long-Term Analysis,

Long Term Follow-up of the Prospective Multicenter Study of reduced-Intensity Allogeneic Stem Cell Transplantation for Primary or Post ET/PV Myelofibrosis

Disease-Specific Recovery of Regulatory T Cell After Allogenic Stem Cell Transplantation

Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis

Related Vs Unrelated Donors After Auto-Allo Tandem Stem Cell Transplantation for Newly Diagnosed Patients with Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only